The primary way these medications support weight loss is through delayed gastric emptying
PYY 336 is responsible for the anorexigenic actions of PYY, as documented in infusion studies (111, 112) and together with GLP-1, seems to play a role in the decreased food intake and major weight loss seen after the bariatric surgery procedure, Roux-en-Y gastric bypass (111, 113)
However, if you take insulin, sulfonylureas, or meglitinides concurrently, hypoglycemia risk increases substantially
The focus is not on quickly using a specific active ingredient, but on determining which treatment option is medically appropriate, tolerable, available, and suitable for long-term medical support
These medications are meant to be combined with a well-balanced, nutritious diet and regular exercise (150 minutes/week) to achieve optimal results